CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growing obese population coupled with rising prevalence of diabetes
4.1.2. Increasing market demand for human insulin analogues
4.1.3. Technological advancements such as innovation of insulin pens
4.1.4. Favourable medical reimbursement scenario in developed countries
4.1.5. Increasing R&D investments in drug discovery and development
4.2. Market Restraints & Challenges
4.2.1. Stringent regulatory requirements for product approval
4.2.2. The high cost of production and manufacturing complexities
4.2.3. Limited access to human insulin in emerging countries
4.3. Market Opportunities
4.3.1. Expected patent expiry of key human insulin drugs
4.3.2. Pipeline insulin products and untapped emerging economies
4.3.3. Implementation of regulations against needle sticks injuries and others
CHAPTER 5 GLOBAL HUMAN INSULIN MARKET – BY PRODUCT TYPE
5.1. HI Drugs
5.2. HI Delivery Devices
CHAPTER 6 GLOBAL HUMAN INSULIN MARKET – BY TYPE
6.1. Insulin Analogs and Biosimilar
6.1.1. Long-Acting Biosimilar
6.1.2. Rapid-Acting Biosimilar
6.1.3. Premixed Biosimilar
6.2. HI Biologics
6.2.1. Short-Acting Biologics
6.2.2. Intermediate-Acting Biologics
6.2.3. Premixed Biologics
CHAPTER 7 GLOBAL HUMAN INSULIN MARKET – BY BRAND
7.1. HI Analogs and Biosimilar
7.2.1. Lantus
7.2.2. Novo rapid and Novo log
7.2.3. Humalog
7.2.4. Other Brands
7.2. HI Biologics
7.2.1. Actrapid, Mixtard, and Insulatard
7.2.2. Humulin
7.2.3. Insuman
CHAPTER 8 GLOBAL HUMAN INSULIN MARKET – BY DELIVERY DEVICES
8.1. Syringes
8.2. Pens
8.2.1. Disposable Pens
8.2.2. Reusable Pens
8.3. Pen Needles
8.3.1. Standard Pen Needles
8.3.2. Safety Pen Needles
CHAPTER 9 GLOBAL HUMAN INSULIN MARKET – BY APPLICATION
9.1. Type I Diabetes
9.2. Type II Diabetes
CHAPTER 10 GLOBAL HUMAN INSULIN MARKET - BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.2.4. Costa Rica
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Chile
10.3.4. Columbia
10.3.5. Others
10.4. Europe
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Russia
10.4.7. Netherlands
10.4.8. Switzerland
10.4.9. Poland
10.4.10. Others
10.5. Asia Pacific
10.5.1. China
10.5.2. Japan
10.5.3. India
10.5.4. South Korea
10.5.5. Australia & New Zealand
10.5.6. Malaysia
10.5.7. Singapore
10.5.8. Others
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. Iran
10.6.4. Iraq
10.6.5. Qatar
10.6.6. South Africa
10.6.7. Algeria
10.6.8. Morocco
10.6.9. Nigeria
10.6.10. Egypt
10.6.11. Others
CHAPTER 11 GLOBAL HUMAN INSULIN MARKET - COMPANY PROFILES
11.1. Becton, Dickinson and Company
11.2. B. Braun Melsungen AG
11.3. Biocon Limited
11.4. NOVO Nordisk A/S
11.5. Wockhardt Limited
11.6. Ypsomed AG
11.7. GlaxoSmithKline PLC
11.8. Julphar Bangladesh Ltd.
11.9. Eli Lilly and Company
11.10. Albireo Pharma, Inc.
11.11. Tonghua Dongbao Pharmaceutical Co., Ltd.
11.12. Adocia, Merck & Co. Inc.
11.13. Pfizer, Inc.
11.14. Aventis
11.15. SemBioSys
CHAPTER 12 GLOBAL HUMAN INSULIN MARKET - COMPETITIVE
LANDSCAPE
12.1. Market Share Analysis
12.2. Strategies adopted by top companies
13.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 14 MARKET INSIGHTS
14.1. Industry Experts Insights
14.2. Analysts Opinions
14.3. Investment Opportunities
CHAPTER 15 APPENDIX
15.1. List of Tables
15.2. List of Figures
